Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is employed to manage acid‑related gastrointestinal conditions in adults.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole acts on the gastric proton pump to control excessive acid production, making it useful for several acid‑related disorders. - Gastro‑esophageal reflux disease (GERD): relieves heartburn and promotes healing of esophageal irritation. - Erosive esophagitis: accelerates mucosal repair and reduces further erosion. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid caused by gastrin‑producing tumors. - Prevention of NSAID‑induced gastric ulcers: protects the stomach lining when non‑steroidal anti‑inflammatory drugs are used.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may be transient. - Nausea: feeling of stomach upset, sometimes accompanied by loss of appetite. - Abdominal pain: cramping or discomfort in the stomach area. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention. - Clostridioides difficile infection: persistent watery diarrhea indicating colitis. - Low serum magnesium: muscle cramps, weakness, or irregular heartbeat. - Bone fracture risk: especially with long‑term use, due to impaired calcium absorption. - Elevated liver enzymes: indicating possible hepatic stress.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal or hepatic impairment: adjust therapy and monitor function tests. - Long‑term use: evaluate need periodically to avoid bone density loss. - Concomitant infection risk: be alert for signs of gastrointestinal infections. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Discontinuation: taper if therapy has been long‑term to reduce rebound acid hypersecretion. - Store at ambient temperature (below 25°C): keep in the original container, protect from moisture and light.

Pantoprazole may alter the absorption or metabolism of several co‑administered medicines.

Major Interactions (Avoid): - Atazanavir or other protease inhibitors: reduced antiviral absorption, compromising efficacy. - Ketoconazole, itraconazole, or other acid‑dependent antifungals: markedly decreased bioavailability. - Rilpivirine: diminished plasma concentrations, risking therapeutic failure.

Moderate Interactions (Monitor Closely): - Clopidogrel: reduced conversion to active metabolite, potentially lowering antiplatelet effect. - Digoxin: increased serum levels, requiring dose adjustment. - Methotrexate (high dose): decreased renal clearance, necessitating monitoring of toxicity.